Seizure recurrence after GLP ‐1 receptor agonist initiation in adults with epilepsy
Epilepsia · 2026
DOI: 10.1111/epi.70022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia, 2026. Verfasst von Majd A AbuAlrob und 5 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Institute, Hamad Medical Corporation, Doha, Qatar. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Epilepsy, Hypoglycemic Agents, Seizures. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Objective
To examine whether initiation of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) is associated with seizure recurrence and related outcomes in adults with epilepsy and type 2 diabetes.
Methods
We conducted a retrospective cohort study using de‐identified electronic health records from the TriNetX Research Network (January 2003–August 2025), including adults ≥18 years with ≥3 epilepsy or recurrent seizure diagnoses. Patients initiating a GLP‐1 RA (exenatide, liraglutide, dulaglutide, lixisenatide, semaglutide, or tirzepatide) without prior comparator therapy were compared with those initiating other glucose‐lowering agents (sodium–glucose cotransporter 2 inhibitors, dipeptidyl peptidase 4 inhibitors, sulfonylureas, or insulin) without GLP‐1 RA exposure. Propensity score matching (1:1) was performed on 82 covariates, yielding 8688 matched pairs. Outcomes were assessed using Cox proportional hazards models.
Results
After matching, the mean age was 52.6 years, and 67.6% were female. Median follow‐up was 514 days (interquartile range [IQR] 671) for GLP‐1 RA initiators and 415 days (IQR 769) for comparators. GLP‐1 RA initiation was associated with lower risk of seizure recurrence (HR .82, 95% confidence interval [CI] .78–.86; RD −2.1%), hospitalization (HR .35, 95% CI .29–.43; RD −2.6%), and all‐cause mortality (HR .40, 95% CI .34–.47; RD −4.8%). Associations with status epilepticus (HR .75, 95% CI .66–.85; RD −.7%) and ICU admission (HR .82, 95% CI .69–.96; RD −.3%) were smaller; the latter was not statistically significant. Significance In this large multinational cohort, GLP‐1 RA initiation was associated with reduced risks of seizure recurrence, hospitalization, and mortality compared with other glucose‐lowering therapies. These hypothesis‐generating findings warrant confirmation in prospective studies before translation into clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroscience Institute, Hamad Medical Corporation, Doha, Qatar.
- Department of Internal Medicine, Virtua Health, Camden, USA.
- Department of Internal Medicine, Jenin Governmental Hospital, Palestinian Health Ministry, Nablus, Palestine.
ORCID-Profile: Majd A AbuAlrob, Abdullah Hussein, Rand Abdellatif, Adham Itbaisha, Khaled Zammar, Boulenouar Mesraoua
Zitieren
APA
AbuAlrob, M. A., Hussein, A., Abdellatif, R., Itbaisha, A., Zammar, K., & Mesraoua, B. (2026). Seizure recurrence after GLP ‐1 receptor agonist initiation in adults with epilepsy. Epilepsia. https://doi.org/10.1111/epi.70022
Vancouver
AbuAlrob MA, Hussein A, Abdellatif R, Itbaisha A, Zammar K, Mesraoua B. Seizure recurrence after GLP ‐1 receptor agonist initiation in adults with epilepsy. Epilepsia. 2026. doi:10.1111/epi.70022
BibTeX
@article{AbuAlrob2026,
author = {AbuAlrob, Majd A and Hussein, Abdullah and Abdellatif, Rand and Itbaisha, Adham and Zammar, Khaled and Mesraoua, Boulenouar},
title = {Seizure recurrence after GLP ‐1 receptor agonist initiation in adults with epilepsy},
journal = {Epilepsia},
year = {2026},
doi = {10.1111/epi.70022}
}
EUVIMED